Viatris Inc. · NASDAQ:VTRS
Viatris — Investor Presentation (August 2020)
14 slides from Viatris's investor presentation, August 2020
Slide 1: Path to Shareholder Value Creation
Path to Shareholder Value Creation VIATRIS TSR Execution Plan August 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This communication contains “forward-looking statements”. Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (“Newco”) and Mylan N.V. (“Mylan”), which will immediately follow the proposed separation of
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale
Slide 4: Non-GAAP Financial Measures
Non-GAAP Financial Measures Mylan is not providing forward looking information for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable c
Slide 5: Introducing VIATRIS' New Executive Management Team
Introducing VIATRIS’ New Executive Management Team + + + OVERALL STRATEGIC BUSINESS AND FINANCIAL PERFORMANCE OVERSIGHT AND OPERATIONAL PERFORMANCE AND AND STRATEGY LEADERSHIP EXECUTION DISCIPLINE DEVELOPMENT Robert J. Coury Michael Goettler Rajiv Malik Sanjeev Narula Executive Chairman Chief Execut
Slide 6: VIATRIS – Path to Shareholder Value Creation
VIATRIS – Path to Shareholder Value Creation Description Page No. Stage 1 Close Transaction 7 Immediate initiation of VIATRIS’ new business model, including planned initiation of dividend of at least Stage 2 25% of free cash flow* starting first full quarter after the close and opening guidance for
Slide 7: Anticipated Transaction Close – 4Q 2020
Anticipated Transaction Close – 4Q 2020 Ongoing Integration Planning Announce New Company Name Determined that VIATRIS will be Listed on Nasdaq Announce VIATRIS Director Appointments Announce VIATRIS Chief Financial Officer Receive Mylan Shareholder Approval Receive Regulat
Slide 8: How the Business Model will Transform
How the Business Model will Transform Combination Strengthens and Scales the Balance Sheet, Enhances Financial Flexibility and Transitions the Business Model to a Capital Return Focus Build scale and enhance geographic reach through Manage balanced capital deployment strategy to Key Focus Areas tran
Slide 9: Clear Roadmap for Execution to Maximize Value Creation
Clear Roadmap for Execution to Maximize Value Creation Adjusted EBITDA* and Earnings* Growth Revenue Growth and Operating Leverage Transaction Close / Initiation of Years New Business Model 0 1 2 3 4 5 6 7+ INTEGRATION Operations SIGNIFICANT PIPELINE PRODUCT LAUNCHES Business New Pipeline Execution
Slide 10: Sustainable Near-Term Adjusted EBITDA Growth Achieved through Synergies
Sustainable Near-Term Adjusted EBITDA* Growth Achieved through Synergies, Pipeline Delivery and Portfolio Rationalization VIATRIS’ enhanced ex-US 2021E pro forma revenue1 exposure of ~70% further strengthens tailwinds to offset anticipated headwinds Near-Term Adjusted EBITDA* Serving 175+ Markets Gl
Slide 11: Deployment of Capital through Global Healthcare Gateway
Deployment of Capital through Global Healthcare GatewayTM Expected to Fuel Long-Term Revenue Growth Establishing VIATRIS as the Partner of ChoiceTM to Create Value for All Stakeholders Unique Capabilities… … to Foster Disciplined Capital Investment Broad Global Commercial Reach Across Channels & The
Slide 12: VIATRIS – Planned Path to Multiple Expansion
VIATRIS – Planned Path to Multiple Expansion Exceptional TSR to be Delivered from the Onset, with Model Transitioning Over Time Drivers of Cumulative Growth Over Time Adjusted EBITDA* and Earnings* Growth Revenue Growth and Operating Leverage 50 Cumulative Growth in Key Metrics 45 Share Repurchases
Slide 13: VIATRIS Well-Positioned for Potential to Re-Rate
VIATRIS Well-Positioned for Potential to Re-Rate Key Characteristics of a New Peer Set Indicate Significant Upside Potential Spec Pharma / Generics Companies VIATRIS Consumer Health Companies Large Cap Pharma 10 Market Cap ($bn) $11 $8 $7 ~$201 $354 $75 $68 $218 $200 $150 2020E – 2024E Revenue CAGR2
Slide 14: Illustrative Total Enterprise Opportunity to Deliver Significant Shareholder Value
Opportunity to Deliver Significant Shareholder Value In addition to returning significant capital to shareholders, VIATRIS has the opportunity to unlock shareholder value through multiple expansion Implied VIATRIS Share Price1 Illustrative VIATRIS Adjusted EBITDA* ($bn) 7.0 7.5 8.0 8.5 Illustrative